Last Updated : July 24, 2024
Details
Generic Name:
pembrolizumab
Project Status:
Not filed
Therapeutic Area:
Primary mediastinal B-cell lymphoma
Manufacturer:
Merck Canada Inc.
Brand Name:
Keytruda
Project Line:
Reimbursement Review
Project Number:
NS0034-000
Biosimilar:
No
Submission Type:
Non-submission
Fee Schedule:
N/A
Indications:
Treatment of adult and pediatric patients with refractory primary mediastinal B-cell lymphoma (PMBCL), or who have relapsed after 2 or more lines of therapy.
Recommendation Type:
Canada’s Drug Agency is unable to recommend reimbursement as a submission was not filed by the manufacturer
Last Updated : July 24, 2024